TrialCurveNK105 vs paclitaxel in metastatic breast cancer: reconstructed Kaplan–Meier curves
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Br J Cancer. 2019 Feb 12;120(5):475–80. doi: 10.1038/s41416-019-0391-z |
|---|---|
| DOI | 10.1038/s41416-019-0391-z |
| Registry | NCT01644890 |
| Phase | Phase 3 |
| Conditions | Breast Cancer Nos Metastatic Recurrent |
| Interventions | NK105, Paclitaxel |
| Sponsor | Nippon Kayaku Co., Ltd. |
| Enrolment | 436 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Full analysis set
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: PTX 8.5 months; NK105 8.4 months. Survival at 12 months: PTX 41%; NK105 34%. Hazard ratio PTX vs NK105 0.81 (95% CI 0.64–1.02).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| PTX | 211 | 130 | 8.5 |
| NK105 | 211 | 146 | 8.4 |
- PTX vs NK105: reconstructed HR 0.81 (95% CI 0.64–1.02)
Landmark survival (reconstructed)
| Time | PTX | NK105 |
|---|---|---|
| 6 mo | 59.1% | 60.0% |
| 12 mo | 41.3% | 33.6% |
| 18 mo | 30.4% | 15.4% |
| 24 mo | 17.5% | 9.2% |
| 36 mo | 10.9% | — |
Checks against the published figure
- NK105 median: printed 8.4, reconstructed 8.42 pass
- PTX median: printed 8.5, reconstructed 8.53 pass
- NK105 events: printed 144, reconstructed 146 pass
- NK105 n: printed 211, reconstructed 211 pass
- PTX events: printed 129, reconstructed 130 pass
- PTX n: printed 211, reconstructed 211 pass
- hazard ratio: printed 1.25, reconstructed 1.24 pass
Overall survival — Full analysis set
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: PTX 36.2 months; NK105 31.2 months. Survival at 12 months: PTX 89%; NK105 85%. Hazard ratio PTX vs NK105 0.83 (95% CI 0.62–1.13).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| PTX | 211 | 80 | 36.2 |
| NK105 | 211 | 90 | 31.2 |
- PTX vs NK105: reconstructed HR 0.83 (95% CI 0.62–1.13)
Landmark survival (reconstructed)
| Time | PTX | NK105 |
|---|---|---|
| 6 mo | 97.1% | 95.2% |
| 12 mo | 89.0% | 85.4% |
| 18 mo | 78.1% | 73.3% |
| 24 mo | 67.8% | 59.2% |
| 36 mo | 50.5% | 46.6% |
Checks against the published figure
- NK105 median: printed 31.2, reconstructed 31.2 pass
- PTX median: printed 36.2, reconstructed 36.2 pass
- NK105 events: printed 90, reconstructed 90 pass
- NK105 n: printed 211, reconstructed 211 pass
- PTX events: printed 80, reconstructed 80 pass
- PTX n: printed 211, reconstructed 211 pass
- hazard ratio: printed 1.2, reconstructed 1.2 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/nk105-vs-paclitaxel-in-metastatic-breast-cancer-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/nk105-vs-paclitaxel-in-metastatic-breast-cancer-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Br J Cancer. 2019 Feb 12;120(5):475–80. doi: 10.1038/s41416-019-0391-z doi:10.1038/s41416-019-0391-z. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/nk105-vs-paclitaxel-in-metastatic-breast-cancer
Report a problem with these data
Related trials
- FURVA: Overall survival; Progression-free survival
- PERSEPHONE: Disease-free survival; Overall survival
- CirCe01: Overall survival; Progression-free survival
- TROIKA (final analysis): Event free survival
- FAKTION: Overall survival; Progression-free survival
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials